Shareholder Tools

Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1999
Press Releases
Date Title and Summary View
Aug 16, 2017 WEST LAFAYETTE, Ind., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the 254th American Chemical Society (ACS) National Meeting...
Aug 8, 2017 - Plans to Initiate Clinical Development for CAR T-Cell Program in Osteosarcoma in 2018 - - Nearing Completion of Enrollment of Expansion Phase of EC1169 Trial in Prostate Cancer Patients - - IND filed for Dual-Targeted DNA Crosslinker EC2629 - - Conference Call Today at 4:30 p.m. EDT - WEST LAFAYETTE, Ind., Aug. 08, 2017 (GLOBE NEWSWIRE...
Aug 1, 2017 WEST LAFAYETTE, Ind., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Tuesday, Aug. 8th, at 4:30 p.m. EDT to discuss its second quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast o...
Jun 2, 2017 - Company Continuing EC1169 Program in Taxane-Exposed Patients, but Ending Clinical Development of EC1456 and of EC1169 in Taxane-Naïve Patients -¬† - Refocusing Efforts on Chimeric Antigen Receptor T-cell (CAR T-cell) and Dual-Targeted DNA Crosslinker Drug EC2629 Programs¬†- - Restructuring to Reduce Workforce by Approximately 40%; Will M...
May 26, 2017 WEST LAFAYETTE, Ind., May 26, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2017 American Society of...
May 10, 2017 WEST LAFAYETTE, Ind., May 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the first quarter ending March 31, 2017, and provided a clinical and pipeline update. "We look...
May 3, 2017 WEST LAFAYETTE, Ind., May 03, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Wednesday, May 10th, at 8:30 a.m. EDT to discuss its first quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast o...
Apr 5, 2017 - Late-breaking poster demonstrates that Endocyte's bi-specific adaptor molecules can mitigate or eliminate cytokine storms - - Potential to meaningfully improve the safety and tolerability of CAR T-cell therapies - WEST LAFAYETTE, Ind., April 05, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small m...
Mar 27, 2017 WEST LAFAYETTE, Ind., March 27, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that eight posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annu...
Mar 10, 2017 WEST LAFAYETTE, Ind., March 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the fourth quarter ending December 31, 2016, and provided a clinical and business update. "W...
1
... NextLast
Add to Briefcase = add release to Briefcase